Global HIV Rapid Test Kit Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global HIV Rapid Test Kit Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Rapid HIV tests are self-contained EIAs that detect HIV in whole blood or oral fluid specimens and can be used at the point of care yielding results within around 30 minutes. Rapid HIV test is a blood-based screening that can detect the presence of antibodies to the human immunodeficiency virus (HIV) in a few minutes. The rapid HIV testing kits are used for collecting venous or finger prick sample and then performed onsite by a healthcare professional who has been trained in its use. The common test kits use blood to determine if an individual is infected with HIV. Other types may be used for saliva detection, which can indicate recent exposure to the virus.

Market Overview:


The latest research study on the global HIV Rapid Test Kit market finds that the global HIV Rapid Test Kit market reached a value of USD 864.54 million in 2022. It’s expected that the market will achieve USD 1309.75 million by 2028, exhibiting a CAGR of 7.17% during the forecast period.

Following a strong rebound in 2021, the global economy is entering a pronounced slowdown amid fresh threats from COVID-19 variants and a rise in inflation, debt, and income inequality that could endanger the recovery in emerging and developing economies, according to the World Banks latest Global Economic Prospects report. Global growth is expected to decelerate markedly from 5.5 percent in 2021 to 4.1 percent in 2022 and 3.2 percent in 2023 as pent-up demand dissipates and as fiscal and monetary support is unwound across the world.

The rapid spread of the Omicron variant indicates that the pandemic will likely continue to disrupt economic activity in the near term. In addition, a notable deceleration in major economiesincluding the United States and Chinawill weigh on external demand in emerging and developing economies. At a time when governments in many developing economies lack the policy space to support activity if needed, new COVID-19 outbreaks, persistent supply-chain bottlenecks and inflationary pressures, and elevated financial vulnerabilities in large swaths of the world could increase the risk of a hard landing.

Professional training issues

Despite the potential for misdiagnosis, the use of rapid tests continues to be an increasingly popular method of HIV screening due to their simplicity and affordability. There has now been a dramatic increase in the number of people able to be tested. The problem is that the number of medical professionals available to administer the tests and interpret the results has not increased proportionally, resulting in clinic staff with less training and experience running testing centers in certain areas. Proponents of rapid testing argue that one of its key advantages is that it requires little training for staff administering the tests, making it possible to conduct widespread testing in low-resource settings. Underestimating the value of staff training is a key flaw in rapid testing methods, as this can adversely affect the quality-of-care patients receive and the accuracy of outcomes. In the United States, training standards for administering rapid HIV testing are not uniform. In most community-based organizations, training programs for clinic staff do not meet the standards set by the Centers for Disease Control and Prevention (CDC). Further complicating the issue, rapid testing technology has evolved so rapidly that training protocols must be updated, and training must be provided on a regular basis to ensure that testing procedures are followed correctly. Unfortunately, evolving technology combined with already poor training standards has resulted in mediocre care and unreliable results for patients seeking rapid HIV testing. The lack of trained professionals to administer the tests affects not only the validity of the results, but also the quality of counseling patients receives. As the use of rapid tests expands, more emphasis must be placed on counselor training. High-quality counseling significantly increases the likelihood that a patient diagnosed with HIV will follow preventive guidelines to reduce HIV transmission and cope better socially and emotionally with his or her diagnosis. The training of professionals is also an important challenge for the market.

The existence of shortcomings

The main disadvantage of rapid testing is a consequence of a testing consideration called 'the window period'. This is the period of time during which a test is not reliable because the particular compound it aims to detect might not be present in sufficient quantities for an accurate result.
Most HIV rapid tests work on the basis of detecting antibodies, defense molecules generated by your body in response to the HIV virus, unfortunately, the flaw to this method is that the test is only reliable when antibodies are present in sufficient quantities. For rapid tests, the window period is the time it takes for antibodies to reach the required amount for reliable detection. This is traditionally up to 3 weeks after the transmission of HIV, although it can vary considerably, and in some cases, the window period can be as long as 6 months.

Region Overview:


Africa is projected to account for a considerable share of the HIV Rapid Test Kit market and is expected to become the largest region by 2027.

Company Overview:


Wantai BioPharm is one of the major players operating in the HIV Rapid Test Kit market, holding a share of 17.43% in 2021.

Abbott

It mainly produces diagnostics, medical devices, and nutritional and branded generic drugs. Abbott's main business is pharmaceuticals, medical devices and nutritional products, and it has carried out several large business acquisitions. Its products are divided into animal health, medical diagnosis, nutritional products, and cardiovascular-related, including animal anesthesia supplies and vascular-related medical equipment, etc.

Wantai BioPharm

Beijing Wantai Biological Pharmacy is one of the leading manufacturers in China of infectious disease diagnostics and a global leader in Hepatitis E diagnostics.

Segmentation Overview:


By type, Blood Detection segment accounted for the largest share of market in 2021.

Blood Detection

Blood Detection Rapid Test Kit is used to detect and diagnose HIV in blood. Blood detection rapid test kits are based on the principle that antibodies produced by a person who has been infected with HIV will react in an antigen-antibody reaction when they come into contact with antigens from the virus particle, which have been immobilized onto a nitrocellulose membrane or other material. The objective of these tests is to determine if someone may be infected as quickly as it takes for them to provide their sample.

Saliva Detection

Saliva detection is the process of detecting HIV in saliva. Saliva detects antibodies that are produced by the body's immune system to fight off a virus on infection, but they will not be detected until weeks after being infected. The test takes about 20 minutes and can detect even very small amounts of viral material before it has been destroyed or degraded over time. Generally, this type of testing is used for people who have difficulty with blood tests such as when a person cannot find a vein because their veins collapse easily (such as those with diabetes).

Application Overview:


The market's largest segment by application is the segment Hospital, with a market share of 68.41% in 2021.

Donating Blood Site

HIV Rapid Test Kit is used in Donating Blood Site for the safety of blood donors and recipients. The test kit can be a great tool to combat HIV/AIDS as well as another major global health issue. A rapid HIV test is used at a blood donation center to immediately identify an individual who may have been exposed to the virus. The goal of this type of testing is for someone who has donated their blood and is not sure if they may be infected with HIV, which can then lead them to get tested.

Hospital

Rapid HIV test kits have various applications in hospitals. The tests are used to detect HIV antibodies or the virus itself, both of which are detectable within a few weeks after infection with HIV. They can also be used as part of an emergency response plan for incident management and monitoring patient exposure. Rapid HIV testing is often preferred when infections may not yet show up on other diagnostic tools because this type of test measures immune responses that occur very early during infection and can detect recent exposures more quickly than antibody tests like ELISA/Western blot analysis (ELISPOT). Hospitals use it often to detect the virus quickly.

Key Companies in the global HIV Rapid Test Kit market covered in Chapter 3:

Atomo Diagnostics
Chembio Diagnostic Systems
Abbott
Orasure Technologies
Bio-Rad Laboratories Inc.
Wondfo Biotech
DIALAB GmbH
Autobio Diagnostics
Wantai BioPharm
Kehua Bio-Engineering
MedMira
bioMérieux
bioLytical Laboratories Inc.
Trinity Biotech

In Chapter 4 and Chapter 14.2, on the basis of types, the HIV Rapid Test Kit market from 2018 to 2029 is primarily split into:

Blood Detection
Saliva Detection
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the HIV Rapid Test Kit market from 2018 to 2029 covers:

Donating Blood Site
Hospital
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)